The COOL-AF Phase 2 Registry: COhort of Antithrombotic Use and Clinical Outcomes in Atrial Fibrillation Patients
5
Issued Date
2025-01-01
Resource Type
eISSN
27723747
Scopus ID
2-s2.0-85214467972
Journal Title
JACC: Asia
Volume
5
Issue
1P2
Start Page
191
End Page
202
Rights Holder(s)
SCOPUS
Bibliographic Citation
JACC: Asia Vol.5 No.1P2 (2025) , 191-202
Suggested Citation
Krittayaphong R., Winijkul A., Rungpradubvong V., Apiyasawat S., Phrommintikul A., Chantrarat T., Methavigul K., Chichareon P., Makarawate P., Wongtheptien W., Kaolawanich Y., Lip G.Y.H. The COOL-AF Phase 2 Registry: COhort of Antithrombotic Use and Clinical Outcomes in Atrial Fibrillation Patients. JACC: Asia Vol.5 No.1P2 (2025) , 191-202. 202. doi:10.1016/j.jacasi.2024.10.027 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/102824
Title
The COOL-AF Phase 2 Registry: COhort of Antithrombotic Use and Clinical Outcomes in Atrial Fibrillation Patients
Author's Affiliation
Siriraj Hospital
Faculty of Medicine, Chiang Mai University
Faculty of Medicine, Khon Kaen University
Faculty of Medicine, Prince of Songkla University
Aalborg University
University of Liverpool
Faculty of Medicine Ramathibodi Hospital, Mahidol University
Phramongkutklao College of Medicine
Faculty of Medicine, Chulalongkorn University
Central Chest Institute of Thailand
Chiangrai Prachanukroh Hospital
Faculty of Medicine, Chiang Mai University
Faculty of Medicine, Khon Kaen University
Faculty of Medicine, Prince of Songkla University
Aalborg University
University of Liverpool
Faculty of Medicine Ramathibodi Hospital, Mahidol University
Phramongkutklao College of Medicine
Faculty of Medicine, Chulalongkorn University
Central Chest Institute of Thailand
Chiangrai Prachanukroh Hospital
Corresponding Author(s)
Other Contributor(s)
Abstract
Background: Atrial fibrillation (AF) is a common condition leading to an increased risk of death and complications such as stroke. Even though direct oral anticoagulants (DOACs) can reduce the risk of ICH, the rate of DOAC use remains low in many Asian countries because of cost concerns. Objectives: The purpose of this protocol paper of the COOL-AF (COhort of antithrOmbotic use and cLinical outcomes in patients with Atrial Fibrillation) Phase 2 registry is to determine the rate of clinical outcome, changes in antithrombotic patterns, and their impact on clinical outcomes, and to develop a prediction model for clinical outcomes. Methods: The COOL-AF Phase 2 study is a prospective observational multicenter study of patients with known or newly diagnosed nonvalvular AF in Thailand. The aim is to achieve a sample size of 3,667 patients from 33 centers. Patients will be followed up every 6 months for up to 3 years. Data collection on and doses of oral anticoagulants (warfarin, dabigatran, rivaroxaban, apixaban, and edoxaban) and antiplatelets are collected. The study outcomes include death, ischemic stroke/systemic embolism, major bleeding, myocardial infarction, heart failure, and quality of life. All events will be adjudicated. Results: Enrollment started in June 2024. The results of the COOL-AF phase 2 registry will be reported when enrollment is complete and one year of follow-up data is available. Conclusions: The COOL-AF Phase 2 trial will provide valuable information about the real-world practice of AF management and outcomes in Asia, which should be able to improve AF outcomes in the future. (COhort of antithrOmbotic Use and cLinical Outcomes in Patients With Atrial Fibrillation [COOL-AF] Phase 2; NCT06396299)